NASDAQ biotech stock on the verge of FDA approval reaches for the sky

Dear Reader, Sometimes you just know when a company is onto something BIG. Since we began talking about this NASDAQ-listed cancer diagnostics company, it has continued to impress us. When we first heard about this company, it was trading at under $4 per share. Since then, this stock has [continued to break the $5 mark, reaching as high as $5.85.]( And it’s not just the rising stock price that is impressive about this company. Apart from [increasing the revenue of its breakthrough product by over 150% in 2022]( this company has continued to churn out exciting news directly related to its revenue growth. Just imagine where this company will be once it gains FDA approval, which is getting closer by the day. If you had gotten in when we first started talking about this company, you’d already be [celebrating some pretty big gains.]( But, with the stream of wins over the last couple of weeks, it’s clear this stock is just getting started. This is a captivating story you definitely don't want to miss. [Click here to get the name and the symbol of this red-hot stock today]( ___________________________________________________________ Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities. 2563 cherry hill ln, Hermitage, PA 16148, United States You may [unsubscribe]( or [change your contact details]( at any time. [Powered by:](